drugset / Trial / NCT02290379
Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
Single-center, randomized, double-blind, placebo-controlled, single ascending dose, safety and tolerability study of TNX-201 capsules in healthy volunteers.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-05
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Racemic isometheptene | Unknown | 70 mg | — |
| Subject | TNX-201 | Small molecule | 35 mg | — |
| Subject | TNX-201 | Small molecule | 70 mg | — |
| Subject | TNX-201 | Small molecule | 140 mg | — |
Indications
No indication recorded.